Volumetric Modulated Arc Therapy Research Articles

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. Eligible patients with newly diagnosed, high-risk (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status), locally advanced, histologically confirmed, squamous cell carcinoma, adenocarcinoma, or adenosquamous cervical cancer were randomly assigned 1:1 to receive five cycles of pembrolizumab (200 mg) or placebo every 3 weeks with concurrent chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Pembrolizumab or placebo and cisplatin were administered intravenously. Patients were stratified at randomisation by planned external beam radiotherapy type (intensity-modulated radiotherapy [IMRT] or volumetric-modulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at screening (FIGO 2014 stage IB2-IIB node positive vs III-IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70 Gy vs ≥70 Gy [equivalent dose of 2 Gy]). Primary endpoints were progression-free survival per RECIST 1.1 by investigator or by histopathological confirmation of suspected disease progression and overall survival defined as the time from randomisation to death due to any cause. Safety was a secondary endpoint. Between June 9, 2020, and Dec 15, 2022, 1060 patients at 176 sites in 30 countries across Asia, Australia, Europe, North America, and South America were randomly assigned to treatment, with 529 patients in the pembrolizumab-chemoradiotherapy group and 531 patients in the placebo-chemoradiotherapy group. At the protocol-specified second interim analysis (data cutoff Jan 8, 2024), median follow-up was 29·9 months (IQR 23·3-34·3). Median overall survival was not reached in either group; 36-month overall survival was 82·6% (95% CI 78·4-86·1) in the pembrolizumab-chemoradiotherapy group and 74·8% (70·1-78·8) in the placebo-chemoradiotherapy group. The hazard ratio for death was 0·67 (95% CI 0·50-0·90; p=0·0040), meeting the protocol-specified primary objective. 413 (78%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 371 (70%) of 530 in the placebo-chemoradiotherapy group had a grade 3 or higher adverse event, with anaemia, white blood cell count decreased, and neutrophil count decreased being the most common adverse events. Potentially immune-mediated adverse events occurred in 206 (39%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 90 (17%) of 530 patients in the placebo-chemoradiotherapy group. This study is registered with ClinicalTrials.gov, NCT04221945. Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer These data, together with results from the first interim analysis, support this immuno-chemoradiotherapy strategy as a new standard of care for this population. Merck Sharp & Dohme, a subsidiary of Merck & Co.

Evaluation of the geometric and dosimetric accuracies of deformable image registration of targets and critical organs in prostate CBCT-guided adaptive radiotherapy.

Kilovoltage cone beam computed tomography (kVCBCT)-guided adaptive radiation therapy (ART) uses daily deformed CT (dCT), which is generated automatically through deformable registration methods. These registration methods may perform poorly in reproducing volumes of the target organ, rectum, and bladder during treatment. We analyzed the registration errors between the daily kVCBCTs and corresponding dCTs for these organs using the default optical flow algorithm and two registration procedures. We validated the effectiveness of these registration methods in replicating the geometry for dose calculation on kVCBCT for ART. We evaluated three deformable image registration (DIR) methods to assess their registration accuracy and dose calculation effeciency in mapping target and critical organs. The DIR methods include (1) default intensity-based deformable registration, (2) hybrid deformable registration, and (3) a two-step deformable registration process. Each technique was applied to a computerized imaging reference system (CIRS) phantom (Model 062M) and to five patients who received volumetric modulated arc therapy to the prostate. Registration accuracy was assessed using the 95% Hausdorff distance (HD95) and Dice similarity coefficient (DSC), and each method was compared with the intensity-based registration method. The improvement in the dCT image quality of the CIRS phantom and five patients was assessed by comparing dCT with kVCBCT. Image quality quantitative metrics for the phantom included the signal-to-noise ratio (SNR), uniformity, and contrast-to-noise ratio (CNR), whereas those for the patients included the mean absolute error (MAE), mean error, peak signal-to-noise ratio (PSNR), and structural similarity index measure (SSIM). To determine dose metric differences, we used a dose-volume histogram (DVH) and 3.0%/0.3mm gamma analysis to compare planning computed tomography (pCT) and kVCBCT recalculations with restimulated CT images used as a reference. The dCT images generated by the hybrid (dCTH) and two-step (dCTC) registration methods resulted in significant improvements compared to kVCBCT in the phantom model. Specifically, the SNR improved by 107% and 107.2%, the uniformity improved by 90% and 75%, and the CNR improved by 212.2% and 225.6 for dCTH and dCTC methods, respectively. For the patient images, the MAEs improved by 98% and 94%, the PSNRs improved by 16.3% and 22.9%, and the SSIMs improved by 1% and 1% in the dCTH and dCTC methods, respectively. For the geometric evaluation, only the two-step registration method improved registration accuracy. The dCTH method yielded an average HD95 of 12mm and average DSC of 0.73, whereas dCTC yielded an average HD95 of 2.9mm and average DSC of 0.902. The DVH showed that the dCTC-based dose calculations differed by <2% from the expected results for treatment targets and volumes of organs at risk. Additionally, gamma indices for dCTC-based treatment plans were >95% at all points, whereas they were <95% for kVCBCT-based treatment plans. The two-step registration method outperforms the intensity-based and hybrid registration methods. While the hybrid and two-step-based methods improved the image quality of kVCBCT in a linear accelerator, only the two-step method improved the registration accuracy of the corresponding structures among the pCT and kVCBCT datasets. A two-step registration process is recommended for applying kVCBCT to ART, which achieves better registration accuracy for local and global image structures. This method appears to be beneficial for radiotherapy dose calculation in patients with pelvic cancer.

Personalized selection of unequal sub-arc collimator angles in VMAT for multiple brain metastases

PurposeInvestigating the effects of unequal sub-arc personalized collimator angle selection on the quality of Volumetric Modulated Arc Therapy (VMAT) plans for treating multiple brain metastases. MethodsThis study included 21 patients, each with 2–4 target volumes of multiple brain metastases. Two stereotactic radiotherapy (SRT) approaches were utilized: sub-arc collimator VMAT (SAC-VMAT) and fixed collimator VMAT (FC-VMAT). In the SAC-VMAT group, multi-leaf collimators (MLC) shaped the target area, dividing the full arc into four unequal sub-arcs under the beam's eye view (BEV). Each sub-arc had an appropriate collimator angle selected to mitigate ‘island blocking problems'. Conversely, the FC-VMAT group used a fixed collimator angle of 15° or 345°. A comparative analysis of the dosimetric parameters of the target volumes and normal tissues, along with the monitor units (MU), was conducted between the two groups. ResultsThe mean dose and dose-volume to normal brain tissue (2–26 Gy, with a step of 2 Gy) were significantly lower in the SAC-VMAT group (P < 0.01). There was no statistical difference between the two groups in dose to the target volumes, conformity index (CI), homogeneity index (HI), and other normal tissues (P > 0.05). Compared with the FA-VMAT group, the SAC-VMAT group significantly reduced the gradient index (GI) (4.5 ± 0.59 vs 5.2 ± 0.75, P < 0.001) and MU (1774.33 ± 181.77 vs 2001.0 ± 344.86, P < 0.001). Notably, with an increase in the number of PTV, the SAC-VMAT group demonstrated more significant improvements in the dose-volume of normal brain tissue, GI, and MU. ConclusionsIn this study, personalized selection of the unequal sub-arc collimator angle ensured the prescribed dose to the PTV, CI, and HI, while significantly reducing the GI, MU, and the dose to normal brain tissue in the VMAT plan for multi-target brain metastases in the cohort of cases with 2–4 target volumes. Particularly as the number of targets increase, the advantages of this method become more pronounced.

Technical Note: Investigating of dosimetric leaf gap and leaf transmission factor variations across gantry and collimator angles in volumetric modulation arc therapy.

This study investigates the influence of gantry and collimator angles on the dosimetric leaf gap (DLG) and leaf transmission factor (LTF) in a Varian LINAC equipped with rounded-end multi-leaf collimators (MLCs). While Varian guidelines recommend DLG measurements at zero degrees for both gantry and collimator, this research aims to address the knowledge gap by assessing DLG and LTF variations at different gantry and collimator angles. Measurements were conducted using a Varian TrueBeam LINAC with a Millennium 120-leaf MLC and Eclipse TPS version 16.1. The beams utilized in this study had energies of 6 MV, 10 MV, 6 FFF, and 10 FFF. LTF and DLG were determined using ionization chambers in solid water phantoms at various gantry angles (0°, 45°, 90°, 135°, 180°, 225°, 270°, and 315°). For each gantry angle, measurements were also taken at various collimator angles (0°, 45°, 90°, and 315°). Dosimetric impacts were evaluated through VMAT Picket Fence tests and patient-specific verification using portal dosimetry for 10 clinical VMAT plans. LTF values showed no significant variation across gantry and collimator angles. However, DLG values exhibited notable differences depending on the gantry angle and were independent of the collimator angle. The highest DLG value was observed at a gantry angle of 270 degrees, while the lowest was at 90 degrees. The AXB DLGAverage (averaging seven measurements of DLGs at different gantry angles) model demonstrated the best agreement between measured and calculated dose distributions, indicating the importance of considering averaged DLG values across multiple gantry angles for accurate dose calculations. Our study highlights the variability of DLG with gantry angle alterations, contrary to Varian guidelines recommending DLG measurements at zero gantry angle only. We advocate for utilizing an averaged DLG value from measurements across multiple gantry angles, as outlined in our methodology.

Investigation of the linear accelerator low dose rate mode for pulsed low-dose-rate radiotherapy delivery

Purpose. Pulsed volumetric modulated arc therapy (VMAT) was proposed as an advanced treatment that combines the biological benefits of pulsed low dose rate (PLDR) and the dosimetric benefits of the intensity-modulated beams. In our conventional pulsed VMAT technique, a daily fractional dose of 200 cGy is delivered in 10 arcs with 3 min intervals between the arcs. In this study, we are testing the feasibility of pulsed VMAT that omits the need to split into ten arcs and excludes any beam-off gaps. Methods. The study was conducted using computed tomographic images of 24 patients previously treated at our institution with the conventional PLDR technique. Our newly installed Elekta machine has a low dose rate option on the order of 25 MU min−1. PLDR requires an effective dose rate of 6.7 cGy min−1 with attention being paid to the maximum dose received within any point within the target not to exceed 13 cGy min−1. The quality of treatment plans was judged based on dose-volume histograms, isodose distribution, dose conformality to the target, and target dose homogeneity. The dose delivery accuracy was assessed by measurements using the MatriXX Evolution 2D array system. Results. All cases were normalized to cover 95% of the target volume with 100% of the prescription dose. The average conformity index was 1.03 ± 0.08 while the average homogeneity index was 1.05 ± 0.02. The maximum reported dose rate at any point within the target was 10.44 cGy min−1. The mean dose rate for all pulsed VMAT plans was 6.88 ± 0.1 cGy min−1. All cases passed our gamma analysis with an average passing rate of 99.00% ± 0.48%. Conclusion. The study showed the applicability of planning pulsed VMAT using Eclipse and its successful delivery on our Elekta linac. Pulsed VMAT using the machine’s low dose rate mode is more efficient than our previous pulsed VMAT delivery.

Optimum delineation of skin structure for dose calculation with the linear Boltzmann transport equation algorithm in radiotherapy treatment planning.

This study investigated the effectiveness of placing skin-ring structures to enhance the precision of skin dose calculations in patients who had undergone head and neck volumetric modulated arc therapy using the Acuros XB algorithm. The skin-ring structures in question were positioned 2mm below the skin surface (skin A) and 1mm above and below the skin surface (skin B) within the treatment-planning system. These structures were then tested on both acrylic cylindrical and anthropomorphic phantoms and compared with the Gafchromic EBT3 film (EBT3). The results revealed that the maximum dose differences between skins A and B for the cylindrical and anthropomorphic phantoms were approximately 12% and 2%, respectively. In patients 1 and 2, the dose differences between skins A and B were 9.2% and 8.2%, respectively. Ultimately, demonstrated that the skin-dose calculation accuracy of skin B was within 2% and did not impact the deep organs.

Effects of electron density force to 1.0 and fill to 1.0 on VMAT treatment plans for lung SBRT.

The aim of this study is to determine the effect of forcing and filling the electron density (ED) to 1.0 of the planning target volume (PTV) overdose distribution in lung SBRT treatment leading to shortening patient treatment time and increasing patient comfort by reducing MU/fraction due to ED manipulation effect. In this study, 36 lung SBRT plans of 12 suitable patients who prescribed a total dose of 50Gy in five fractions were generated with Monaco v.5.10 TPS using the Monte Carlo (MC) algorithm and volumetric modulated arc therapy (VMAT) technique by PTV ED values forcing as well as filling to 1.0 and comparatively assessed. The first group of plans was created by using the patient's original ED, second and third groups of plans were reoptimized by forcing and filling the ED of PTV to 1.0, respectively, therefore acquiring a new dose distribution which lead to comparatively assessment the effects of changes in ED on PTV and OAR doses. Assessment of treatment plans revealed that mean MU/fx numbers were decreased by 76% and 75.25% between Groups 1 and 2, Groups 1 and 3, respectively. The number of segments was also reduced in Group 1 by up to 15% compared with Groups 2 and 3. Maximum HI and CI differences for PTV between Groups 1 and 2 were less than 1% and Groups 1 and 3 were 1.5% which indicates all 3 group plans were comparable in terms of dose distribution within PTV. Forcing and filling the ED of PTV to 1.0 strategy has provided reduced a number of segments and MU/fx without a significant change in PTV mean and maximum doses, thereby decreasing treatment time and patient discomfort during treatment. This process should be considered in line of a potential number of patients as well as prescribed dose and MU/fx numbers.

Dose prediction for cervical cancer in radiotherapy based on the beam channel generative adversarial network

BackgroundExisting deep learning methods, such as generative adversarial network (GAN) technology, face challenges when dealing with mixed datasets, which involve a combination of Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT). This issue significantly complicates the application of dose prediction in the field of radiotherapy. In this study, we propose a novel approach called beam channel GAN (Bc-GAN) to address the task of radiation dose prediction for mixed datasets. Bc-GAN introduces a dose prediction calculation method that requires less precision. By defining an approximate range for dose prediction, Bc-GAN limits the physical range of GAN prediction, resulting in more reasonable dose distribution predictions. MethodsWe adopt a beam angle weighting method to determine the beam angle in the dose calculation. The dose of the beam with the highest weight is calculated using medical images and is then inputted into the artificial intelligence dose prediction model as the input channel. Additionally, we collect data from a total of 346 patients with Cervical Cancer (CC) for dataset. After cleaning the data, we exclude 51 cases with incomplete organ delineation, leaving us with 295 cases (IMRT: VMAT = 137:158) randomly divided into three sets: the training set, the validation set, and the test set, with proportions of 205:60:30, respectively. The assessment of model predictions was conducted via an analysis of dose distributions on the tomographic plane, dose volume histogram (DVH), and dosimetric parameters within the target zones and organs at risk (OAR). ResultsAfter DVH analysis, minimal discrepancy was found between predicted and actual dose distributions in PTV and OAR. The predicted distribution aligned with clinical standards. Dosimetric parameters for PTV were generally lower in the predicted model, except for homogeneity index (HI) (0.238 ± 0.024, P = 0.017) and Dmax (53.599 ± 0.710 Gy, P = 1.8e-05). The prediction model varied in estimating doses for six organs. Specifically, small intestine showed higher V20 (67.92 ± 51.64 %, P = 0.019) and V30 (57.171 ± 1.213 %, P = 0.024) than manual planning. A similar trend was seen in colon's V30 (37.13 ± 61.14 %, P = 0.016). However, predicted bladder V30 (87.51 ± 41.44 %, P = 2.03e-16) was lower, indicating significant dosimetric differences. ConclusionOverall, this study presents an innovative prediction method for CC in radiotherapy using the Bc-GAN model, addressing the challenges posed by different radiotherapy techniques. The proposed approach allows IMRT and VMAT in radiotherapy to be used as training sets, enabling the potential for large-scale engineering and commercialization applications of artificial intelligence (AI). The Bc-GAN-based prediction method for CC in radiotherapy not only reduces the amount of data needed for the training set but also expedites the model generation process. This approach can be applied to guide the development of clinical radiation therapy plans. Furthermore, future studies should consider extending the dose prediction method to encompass other types of tumors.

Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.

This study aimed to investigate the long-term clinical outcomes and toxicities of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) vs. CCRT alone in patients with non-operable esophageal squamous cell carcinoma (ESCC). Between 2008 and 2022, 271 ESCC patients who received definitive CCRT based on intensity modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) were enrolled. Through a propensity score-matched (PSM) method, 71 patients receiving IC and CCRT were matched 1:1 to patients who received CCRT alone. The Kaplan-Meier method and Cox proportional hazards model were applied to analyze survival and prognosis. The IC + CCRT group had no improvement in 5-year overall survival (OS) rate, recurrence-free survival (RFS) rate, and distant metastasis-free survival (DMFS) rate (all p > 0.05) compared with the CCRT group. The 5-year OS rate (65.6% vs. 17.6% vs. 29.3%, p < 0.001), RFS rate (65.6% vs. 17.6% vs. 26.9%, p < 0.001), and DMFS rate (62.5% vs. 10.3% vs. 27.2%, p < 0.001) of the IC good responders were significantly higher than that of the IC poor responders and CCRT group. Multivariate analysis revealed that total radiotherapy time (≥ 49 days) and stage III/IV were independent predictive factors of OS, RFS, and DMFS. No significant differences were observed in the rates of grade 3-4 toxicities between both groups. Our results showed the addition of IC to CCRT was not superior to CCRT in unselected ESCC patients, while IC responders could benefit from this regime without an increase in toxicities.

88 Clinical Implementation of Same Day Volumetric Modulated Arc Therapy in a Rapid Access Palliative Radiotherapy Clinic Using an Automated Planning Script

88 Clinical Implementation of Same Day Volumetric Modulated Arc Therapy in a Rapid Access Palliative Radiotherapy Clinic Using an Automated Planning Script

122 Effect of Different Treatment Planning Optimizers on Stereotactic Ablation Radiotherapy (SABR) Volumetric Modulated ARC Therapy (VMAT) Plans

122 Effect of Different Treatment Planning Optimizers on Stereotactic Ablation Radiotherapy (SABR) Volumetric Modulated ARC Therapy (VMAT) Plans

95 Volumetric Modulated ARC Therapy for Delivering 26GY in Five Fractions Using the Fast-Forward Protocol in Ultra-Hypofractionated Whole Breast Radiation Therapy for Breast Cancer

95 Volumetric Modulated ARC Therapy for Delivering 26GY in Five Fractions Using the Fast-Forward Protocol in Ultra-Hypofractionated Whole Breast Radiation Therapy for Breast Cancer

COMPARATIVE RADIATION DOSIMETRY OF WHOLE BREAST RADIOTHERAPY USING IMRT AND VMAT TECHNIQUES IN LEFT SIDED BREAST CANCER PATIENTS AFTER BREAST CONSERVING SURGERY

Background:The radiotherapy of left sided breast cancers is mandatory and integral part of treatment and challenging because of surrounding critical structures posing increased risk of complications. The main objective of this study was to quantify doses toorgan at risk(OARs) including left lung, heart, contralateral breast, spinal cord, and planning target volume (PTV) using different radiation techniques like Intensity modulated radiation therapy (IMRT)&amp;volumetric modulated arc therapy (VMAT) and comparison of radiation dosimetry. Methods: A prospective study of 30 patients of left sided breast cancer who had undergone Breast Conservative Surgery (BCS) and chemotherapy was done for adjuvant radiation. For every patient radiation planning was done by two different techniques IMRT and VMAT. Then the comparison of radiation dosimetry parameters was done for all the techniques including the parameters like PTV coverage, doses to OAR like heart, left lung, contralateral breast and spinal cord and head of humerus. The Homogenity Index (HI) were calculated. Result: The Mean age of the patient was 46.7 years. When comparing the doses delivered in IMRT and VMAT Technique for left sided breast cancer post breast conservation surgery there was significant difference in PTV Breast and axilla V95 Gy. It was 96.2±1.9% (IMRT) vs 94.8±1.71% (VMAT), (p=0.004). However significant sparing of Organs at Risk was seen. With ipsilateral lung dose mean V5 Gy was 77.86± 9.68% (IMRT) v/s 83.04± 9.86 % (VMAT), (p=0.0446). Also mean V30 Gy was 14.6±4.82% with IMRT vs 16.54±5.86% with VMAT, (p=0.0169). Heart mean dose was 8.8±1.49 Gy with IMRT and 10.98±3.7 Gy with VMAT, (p=0.0227). Further V30 Gy for Heart was 4.61±3.8% with IMRT and 6.72±4.0% with VMAT, (p=0.0132).No significant difference was seen with IMRT and VMAT technique for contralateral lung, contralateral breast and spinal cord. Conclusion: In treatment of patients with radiation with left breast cancer patients post BCS using IMRT and VMAT technique it is seen significant dose reduction with IMRT Technique for ipsilateral lung and Heart as compared to VMAT technique. Significant V95 coverage for PTV Breast and axilla with IMRT as compared to VMAT. Hence in our Study IMRT technique was found to be superior for better sparing of Organ at risk and better PTV coverage.

Global assessment of swallow function (GASF) following VMAT radiotherapy for head and neck squamous cell carcinoma

AimThis study aimed to conduct a global assessment of swallow function (GASF) using a range of swallow outcome tools, in a cohort of patients pre- and post-treatment with image-guided volumetric modulated arc therapy (VMAT) radiotherapy. Materials and methodsAll patients receiving radical (chemo)radiation for SCC of the larynx, oro-, hypo- or nasopharynx between October 2016 – 2021 were eligible for inclusion.Patients were treated with VMAT radiotherapy according to institutional and national protocols.Patients underwent GASF pre- and 6 months post-treatment. Data were collated from the MD Anderson Dysphagia Inventory (MDADI), the Functional Oral Intake Scale (FOIS), the Performance Status Scale-Head and Neck: Normalcy of Diet scale (PSS-NoD), the 100 ml water swallow test (WST) for capacity and maximal interincisal opening (MIO). ResultsOne hundred and seventy-five patients were included. 55.2 % of patients experienced a fall in MDADI-Composite score greater than the published meaningful clinical important difference (MCID).A trend for a decrease in FOIS score reflects a decrease in range of diet textures and increase in reliance on enteral feeding at 6 months post-treatment.Mean PSS-NoD score decreased reflecting increased restriction in diet textures.20 patients’ WST capacity improved by the minimal clinically important difference of > 4mls whilst 37 % of patients experienced a decrease in WST capacity of 4mls or more. 12.6 % of patients developed trismus following radiotherapy. ConclusionsThis paper adds new detail to the understanding of the decline in measured eating, drinking and swallowing function that patients treated with VMAT radiotherapyexperience at 6 months post treatment. However, gaps are highlighted in the evidence base in terms of interpretation of swallow outcomes tool scores; future research in HNC should include ongoing discussion and development around robust outcomes tools and data collection.

Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study

Background and purposePreoperative partial breast irradiation (PBI) is a novel technique that can be used in patients with early-stage breast cancer with the goal of limiting the irradiated breast volume, toxicity and number of fractions. The aim of this trial is to assess the toxicity, surgical, oncologic and cosmetic outcomes of preoperative PBI. Materials and MethodsIn this single-arm phase II trial, we enrolled women ≥ 60 years, with unifocal low-risk breast invasive ductal carcinoma (cT1N0, grade 1–2, ER+, Her2-). Patients were treated with a single fraction of 20 Gy of preoperative PBI using volumetric modulated arc therapy (VMAT). Patients then underwent breast-conserving surgery (BCS) +/- sentinel lymph node biopsy within 72 h of radiation. Primary outcomes were rate of surgical complications and early toxicity. Secondary outcomes were cosmesis at 12 months, chronic toxicity and ipsilateral breast tumor recurrence. ResultsTwenty-five patients were recruited with a median age of 67 years, and a median follow-up of 60 months. Sentinel biopsy was positive in 1 out of 24 patients (4 %). Two patients received adjuvant RT for close margins or positive lymph nodes. Within the first 90 days, none of the patients had surgical complications; almost all had grade 0 to 1 acute and late RTOG skin toxicity. The cosmetic outcome was rated between good and excellent in all cases by physicians and patients, except for one patient who self-rated her cosmesis as fair as of the third year. There were no recurrences. ConclusionPreoperative single-fraction PBI is a safe and feasible treatment for elderly patients with low-risk early-stage breast cancer, with no surgical complications, very low rates of acute and late radiation toxicity, and excellent cosmetic outcomes. Randomized controlled trials are needed to compare preoperative to adjuvant PBI in this patient population.

Postoperative Radiotherapy Using VMAT for RNI Including IMN in Breast Cancer: Report of Short-term Follow-up.

The application of volumetric-modulated arc therapy (VMAT) in postoperative radiotherapy for breast cancer has recently garnered considerable interest, especially when regional lymph node irradiation (RNI), is extended to include the internal mammary node (IMN) region, along with whole-breast or chest wall irradiation. This study aimed to assess both acute and late toxicities, as well as breast cancer outcomes, during the observation period. This retrospective study aimed to assess the safety and feasibility of VMAT in postoperative radiotherapy, including the IMN region, for patients with breast cancer at our hospital. We included 33 eligible patients who received postoperative VMAT radiotherapy, including the IMN region, between November 2018 and July 2021. The primary indications for implementing VMAT were the presence of IMN metastases before primary systemic therapy or more than four axillary lymph node metastases. The median prescribed dose for the chest wall or conserved breast and regional lymph nodes was 50 Gy in 25 fractions. In 16 cases, a simultaneous boost (median, 10 Gy) was administered to residual lymph node metastases. VMAT facilitated a reduction in the mid- or high-dose range to organs at risk, exemplified by V20Gy and V40Gy of the ipsilateral lung, which were 24.10% and 6.84%, respectively, while ensuring adequate target dose irradiation, V45Gy=95.23%. No serious adverse events, including symptomatic radiation pneumonitis, occurred during the 15-month median observation period. Our findings demonstrate the safety and effectiveness of postoperative radiotherapy for breast cancer, including the IMN region, when using VMAT.

Artificial intelligence-based motion tracking in cancer radiotherapy: A review.

Radiotherapy aims to deliver a prescribed dose to the tumor while sparing neighboring organs at risk (OARs). Increasingly complex treatment techniques such as volumetric modulated arc therapy (VMAT), stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and proton therapy have been developed to deliver doses more precisely to the target. While such technologies have improved dose delivery, the implementation of intra-fraction motion management to verify tumor position at the time of treatment has become increasingly relevant. Artificial intelligence (AI) has recently demonstrated great potential for real-time tracking of tumors during treatment. However, AI-based motion management faces several challenges, including bias in training data, poor transparency, difficult data collection, complex workflows and quality assurance, and limited sample sizes. This review presents the AI algorithms used for chest, abdomen, and pelvic tumor motion management/tracking for radiotherapy and provides a literature summary on the topic. We will also discuss the limitations of these AI-based studies and propose potential improvements.

Deep learning for patient-specific quality assurance of volumetric modulated arc therapy: Prediction accuracy and cost-sensitive classification performance

PurposeTo evaluate a deep learning model’s performance in predicting and classifying patient-specific quality assurance (PSQA) results for volumetric modulated arc therapy (VMAT), aiming to streamline PSQA workflows and reduce the onsite measurement workload. MethodsA total of 761 VMAT plans were analyzed using 3D-MResNet to process multileaf collimator images and monitor unit data, with the gamma passing rate (GPR) as the output. Thresholds for the predicted GPR (Th-p) and measured GPR (Th-m) were established to aid in PSQA decision-making, using cost curves and error rates to assess classification performance. ResultsThe mean absolute errors of the model for the test set were 1.63 % and 2.38 % at 3 %/2 mm and 2 %/2 mm, respectively. For the classification of the PSQA results, Th-m was 88.3 % at 2 %/2 mm and 93.3 % at 3 %/2 mm. The lowest cost-sensitive error rates of 0.0127 and 0.0925 were obtained when Th-p was set as 91.2 % at 2 %/2 mm and 96.4 % at 3 %/2 mm, respectively. Additionally, the 2 %/2 mm classifier also achieved a lower total expected cost of 0.069 compared with 0.110 for the 3 %/2 mm classifier. The deep learning classifier under the 2 %/2 mm gamma criterion had a sensitivity and specificity of 100 % (10/10) and 83.5 % (167/200), respectively, for the test set. ConclusionsThe developed 3D-MResNet model can accurately predict and classify PSQA results based on VMAT plans. The introduction of a deep learning model into the PSQA workflow has considerable potential for improving the VMAT PSQA process and reducing workloads.

Semi-automated vertex placement for lattice radiotherapy and dosimetric verification using 3D polymer gel dosimetry.

To evaluate the feasibility of an open-source, semi-automated, and reproducible vertex placement tool to improve the efficiency of lattice radiotherapy (LRT) planning. We used polymer gel dosimetry with a Cone Beam CT (CBCT) readout to commission this LRT technique. We generated a volumetric modulated arc therapy (VMAT)-based LRT plan on a 2 L NIPAM polymer gel dosimeter using our Eclipse Acuros version 15.6 AcurosXB beam model, and also recalculated the plan with a pre-clinical Acuros v18.0 dose calculation algorithm with the enhanced leaf modelling (ELM). With the assistance of the MAAS-SFRThelper software, a lattice vertex diameter of 1.5cm and center-to-center spacing of 3cm were used to place the spheres in a hexagonal, closed packed structure. The verification plan included four gantry arcs with 15°, 345°, 75°, 105° collimator angles. The spheres were prescribed 20Gy to 50% of their combined volume. The 6 MV Flattening Filter Free beam energy was used to deliver the verification plan. The dosimetric accuracy of the LRT delivery was evaluated with 1D dose profiles, 2D isodose maps, and a 3D global gamma analysis. Qualitative comparisons between the 1D dose profiles of the Eclipse plan and measured gel showed good consistency at the prescription dose mark. The average diameter measured 13.3±0.2mm (gel for v15.6), 12.6mm (v15.6 plan), 13.1±0.2mm (gel for v18.0), and 12.3mm (v18.0 plan). 3D gamma analysis showed that all gamma pass percent were>95% except at 1% and 2% at the 1mm distance to agreement criteria. This study presents a novel application of gel dosimetry in verifying the dosimetric accuracy of LRT, achieving excellent 3D gamma results. The treatment planning was facilitated by publicly available software that automatically placed the vertices for consistency and efficiency.

Comparison of two different VMAT radiotherapy TPSs for pancreatic cancer using flattening filter free photon beam energy

BackgroundPancreatic cancer is a devastating disease with a poor prognosis, and radiation therapy plays a crucial role in its treatment and management. Conventional radiation therapy (RT) techniques have limitations in delivering adequate doses to the tumor while sparing surrounding normal tissues. However, modern RT techniques such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT) have led to the development of novel approaches that can reduce toxicity. The incorporation of advanced imaging modalities, like four-dimensional computed tomography (4D-CT) and magnetic resonance imaging (MRI), enables enhancement of tumor control and improves conformality and treatment outcomes. Additionally, using flattening filter-free (FFF) beams can further enhance treatment efficiency and efficacy. PurposeThis study aims to compare two different VMAT techniques using two different treatment planning systems (TPSs), Monaco and Eclipse, in the treatment of pancreatic cancer II stage infiltrating duct carcinoma patients using an FFF photon beam. Materials and methods20 pancreatic cancer II stage infiltrating duct carcinoma patients were retrospectively analyzed, and each patient's plans were designed using the two TPSs. The dose distribution of the target using 6 MV FFF for TrueBeam-Varian and organs at risk (OARs) were compared. The monitor unit (MU), treatment time, conformity (CI), and homogeneity (HI) indices were also evaluated. ResultsFor pancreatic cancer patients, the mean dose of the planning target volume (PTV) in the Monaco plan was lower than the Eclipse plan. The plan evaluation parameters in Monaco and Eclipse were similar without significant differences (p-value = 0.152). The Monaco plan was better than the Eclipse plan regarding mean dose and V15Gy of the kidneys; the spinal cord was lowest in the Monaco plan, and the maximum dose and V45Gy of the spinal cord were 592.1 cGy and 1.37% lower than the Eclipse plan, respectively. ConclusionThe VMAT Monaco plan is a favorable TPS for pancreatic cancer patients, providing improved sparing of critical organs while maintaining adequate target coverage.